SLC9A2 loss enhances colorectal cancer metastasis and immunotherapy resistance by inhibiting STAT3 signaling and angiogenesis, establishing it as a key tumor suppressor and biomarker for colorectal cancer. This evidence concerns the gene SLC9A2 and neoplasm.